DAMORA THERAPEUTICS, INC.
Last · —$18.43-0.13 (-0.70%)live · yahoo · 1h ago
Market cap$1.14B—
P/E · TTM—fwd — · eps —
Beta—vs S&P 500
Div yield—annual · TTM
52w range
——
Volume—session
Loading chart…
OpenFilings analyst
Our analyst
From latest 10-K · 2026-03-19
- Operating Cf Burn
- Accumulated Deficit High
Red flags
- Operating Cf Burn — Negative operating cash flow
- Accumulated Deficit High — Accumulated deficit / equity 203%
Upcoming earnings
9:00 PM UTC+1
Period
Sep 2026
Est. EPS
−$0.40
Est. revenue
0
Press & signals
- GlobeNewswire
Damora Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
- GlobeNewswire
Damora Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
- GlobeNewswire
Damora Therapeutics Reports Second Quarter 2026 Financial Results and Recent Corporate Highlights
The rest of this company's wire — with summaries and source links — is part of Pro.
See plans